• #1212568
  • AbbVie US LLC #00074107001

SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Single-Dose Prefilled Cartridge 2.4 mL

SKYRIZI, INJ 360MG/2.4ML PF CARTRIDGE W/OBI D/S

Features
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • More …
Container Type
Single-Dose Prefilled Cartridge Single-Dose Vial
Strength
60 mg / mL 150 mg / mL
Type
Intravenous Subcutaneous
Volume
1.2 mL 2.4 mL 10 mL
  Log In to Order
or

Product Specifications


Features
  • SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
  • SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
  • 360 mg/2.4 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector
  • Store in a refrigerator at 36°F to 46° F (2°C to 8°C)

Professionals Also Viewed